Moberg Pharma AB (FRA:MB8) LT-Debt-to-Total-Asset: 0.00 (As of Mar. 2026)

What is Moberg Pharma AB LT-Debt-to-Total-Asset?

Moberg Pharma AB FRA:MB8 -1.12% 60 LT-Debt-to-Total-Asset is 0.00 as of Mar. 2026. GuruFocus rates FRA:MB8 with a GF Score™ of 60/100 and a GF Value™ of €1.04. The stock has 1 warning sign investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Moberg Pharma AB's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.00.

Moberg Pharma AB's long-term debt to total assets ratio declined from Mar. 2025 (0.00) to Mar. 2026 (0.00). It may suggest that Moberg Pharma AB is progressively becoming less dependent on debt to grow their business.

Moberg Pharma AB (FRA:MB8) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Moberg Pharma AB LT-Debt-to-Total-Asset Related Terms

Moberg Pharma AB LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Moberg Pharma AB's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Moberg Pharma AB LT-Debt-to-Total-Asset Chart

Moberg Pharma AB Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec21

Dec22

Dec23

Dec24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.48

0.00

0.01

0.00

Moberg Pharma AB Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

60GF Score

Moberg Pharma AB FRA:MB8

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Moberg Pharma AB LT-Debt-to-Total-Asset Calculation

Moberg Pharma AB's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )	/	Total Assets (A: Dec. 2024 )
	=	0.222	/	61.385
	=	0.00

Moberg Pharma AB's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	0.041	/	63.454
	=	0.00

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.00 mean?

Moberg Pharma AB (FRA:MB8) has a LT-Debt-to-Total-Asset of 0.00 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Moberg Pharma AB and its competitors.

Is Moberg Pharma AB's LT-Debt-to-Total-Asset too high?

Moberg Pharma AB's current LT-Debt-to-Total-Asset is 0.00. Overall, Moberg Pharma AB has a GF Score™ of 60/100, reflecting its overall financial health beyond just this single metric.

How does Moberg Pharma AB's LT-Debt-to-Total-Asset compare to ZTS and UTHR?

Moberg Pharma AB's LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?

A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Moberg Pharma AB and its competitors. Moberg Pharma AB's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Moberg Pharma AB stock overvalued right now?

Moberg Pharma AB (FRA:MB8) has a current LT-Debt-to-Total-Asset of 0.00. The stock's GF Value™ is €1.04, compared to a current price of €0.80 — trading 23.6% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.00. Moberg Pharma AB's overall GF Score™ is 60/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Moberg Pharma AB (FRA:MB8), the current LT-Debt-to-Total-Asset is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Moberg Pharma AB (FRA:MB8) Overvalued in 2026?

Based on GuruFocus' analysis, Moberg Pharma AB stock appears to be undervalued. The current stock price of €0.80 is trading 23.6% below its estimated GF Value™ of €1.04.

Key valuation signals for FRA:MB8:

LT-Debt-to-Total-Asset: 0.00
GF Value™: €1.04 vs. price of €0.80 (23.6% below fair value)
GF Score™: 60/100 with 1 warning sign

No single metric tells the full story. See the FRA:MB8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Moberg Pharma AB Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies OSTO:CINPHA OSTO:ENZY OSTO:NANEXA OSTO:KLAR OSTO:EQL OSTO:DICOT XSAT:ACUC OSTO:VIVE OSTO:NEWBRY XSAT:ODI XTER:MRK XSWX:GALD TSE:4502 SHSE:600276 NSE:SUNPHARMA LSE:HLN XTAE:TEVA XSWX:SDZ ZTS UTHR

Other Exchanges MBGPF:USA MOB:Sweden

Address Gustavslundsvagen 42, 5th Floor, Bromma, Stockholm, SWE, SE-167 51

Website https://www.mobergpharma.se

Moberg Pharma AB is a Swedish pharmaceutical company which develops and commercializes proprietary pharmaceuticals based on proven substances. The company develops and markets consumer healthcare products that relieve pain and treat skin conditions, mainly nail fungus. The Company's main product, MOB-015, is a novel topical treatment for onychomycosis It has a single operating segment, the development, and commercialization of medical products. Its geographic areas are Europe, the Americas, and Rest of the world.

60GF Score

Get the complete analysis for FRA:MB8

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.80

Price

€1.04

GF Value

View FRA:MB8 Analysis

See LT-Debt-to-Total-Asset data for all stocks →